These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34498807)

  • 1. Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.
    Hsueh CH; Anderson K; Shen G; Yun C; Qin A; Othman AA
    Clin Transl Sci; 2022 Feb; 15(2):361-370. PubMed ID: 34498807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
    Anderson K; Nelson CH; Gong Q; Alani M; Tarnowski T; Othman AA
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):235-245. PubMed ID: 34468080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
    Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
    Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgotinib: A Clinical Pharmacology Review.
    Namour F; Anderson K; Nelson C; Tasset C
    Clin Pharmacokinet; 2022 Jun; 61(6):819-832. PubMed ID: 35637376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
    Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
    Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
    Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
    Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
    Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
    Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
    Namour F; Fagard L; Van der Aa A; Harrison P; Xin Y; Tasset C
    Br J Clin Pharmacol; 2018 Dec; 84(12):2779-2789. PubMed ID: 30088677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
    Yamazaki T; Desai A; Goldwater R; Han D; Lasseter KC; Howieson C; Akhtar S; Kowalski D; Lademacher C; Rammelsberg D; Townsend R
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):66-75. PubMed ID: 27273004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
    Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
    Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.
    Wang X; Purohit V; Dowty ME; Rodrigues D; Luo L; Mathialagan S; Carey W; Plotka A; Kalluru H; Melissa O; Kaplan J; Huh Y; Vourvahis M; Wolk RM
    J Clin Pharmacol; 2023 Jul; 63(7):784-797. PubMed ID: 36807251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
    Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
    J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
    Xiao G; Rowbottom C; Boiselle C; Gan LS
    Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
    De Buck S; Kucher K; Hara H; Gray C; Woessner R
    Biopharm Drug Dispos; 2018 Sep; 39(8):394-402. PubMed ID: 30171694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
    Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
    J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.